HELP:NASDAQ
Cybin Inc
US$5,16
arrow_downward
-4,44%(-0,24) 1 HR
US$5,25
arrow_upward
+1,80% (+0,093)todaySebelum jam perdagangan normal
Tutup: 28 Apr, 16.00.01 GMT-4 · USD
search
Semua simbol
1 HR
5 HR
1BLN
6BLN
YTD
1THN
5THN
MAKS
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk HELP...
Buka
US$5,38
Tinggi
US$5,50
Rendah
US$5,14
Volume rata-rata
1,13 jt
Volume
775,00
Harga tinggi dalam 52 minggu terakhir
US$8,97
Harga rendah dalam 52 minggu terakhir
US$4,29
Beta
1,03
Saham beredar
50,04 jt
Jumlah karyawan
50
Artikel berita
Dari berbagai sumber di seluruh web
TipRanks
·
15 jam yang lalu
Helus Pharma Aligns With U.S. Veteran Mental Health Push in New TARA Mind Partnership
Investing.com
·
23 jam yang lalu
Helus Pharma partners with TARA Mind for trial recruitment
Stock Titan
·
23 jam yang lalu
Helus and TARA Mind target veterans for depression trial outreach
Profil
Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines.
The company's drug candidates include psilocybin, HLP002, HLP003, HLP004, HLP005, and HLP006. Another drug that the company has developed is CYB210010.
As of January 2025, HLP003 is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development.
In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025. Wikipedia
Tentang Cybin Inc
Konten AI mungkin berisi kesalahan. Pelajari lebih lanjut